As seen below, when developing its recommended preferred alternative to forward GSK1120212 clinical trial to the Commission, in every region the BRTF modified the recommendations developed through the RSG. To ensure transparency and to ensure that the original work of the RSG received due consideration, the BRTF also transmitted to the Commission the final RSG proposals. Under California law, adoption of new MPAs requires Commission public hearings and input, preparation of proposed regulations to accompany each MPA, identification
of a preferred alternative MPA network and analysis of each of the “project alternatives,” as required under the California Environmental Quality Act (CEQA), culminating in a final Commission action designating the MPAs. As discussed below, in each PR-171 nmr of the four study regions the Commission modified the recommendation of the BRTF in selecting its preferred alternative for CEQA review. The CEQA required
project alternatives were developed based on RSG proposals. The Initiative’s work was completed over seven years between 2005 and 2011, with the end of planning in one region overlapping with the launching of information gathering and outreach for the next region (Table 5). State staff, especially from the CDFG, took the lead in regulatory processes after the Initiative BRTF delivered its recommendations to the Commission in a joint meeting. The total time encompassed from initiation of work in a study region to effective regulation for the three completed study regions ranges from 29 to 44 months, with time lengthening in each region. The Initiative was successful at meeting the objectives and timelines of the MOU. Most importantly, the work of the Initiative supported
formal regulatory action Forskolin cost by the Commission establishing an improved network of MPAs in California. Some of the over 60 existing MPAs in the state were terminated, many existing MPAs were changed spatially or in allowed uses and many wholly new MPAs were established. Success is not merely the result of technical expertise, application of the best science, stakeholder involvement or effective management of a complex process. Nominally, under the MOU structuring the Initiative, the MPA proposals forwarded by the BRTF at the end of each study region had to meet the requirements of the MLPA and be based on robust stakeholder processes informed by sound science. However, these technical factors should be considered “necessary, but not sufficient” for success, which also required political skill of those participating in the Initiative. The BRTF recommendation of a preferred alternative had to be politically plausible and the processes had to compel action by the Commission.